Patent

Data

Cmpds

HGNC*

Patent Title

Organization

Deposition

Downloads

98

1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins

Incyte Corporation; Incyte Holdings Corporation

08/18/23

2D 3D TSV

364

Bicyclic-fused heteroaryl or aryl compounds

Pfizer Inc.

08/18/23

2D 3D TSV

8

HGNC:6840 6842

Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition

GENUV Inc.

08/18/23

2D 3D TSV

36

HGNC:171 1076 172 175

Compounds and methods of use

Medivation Technologies LLC

08/18/23

2D 3D TSV

2

HGNC:6190 6192 6193 12440

Crystalline hydrate of a JAK inhibitor compound

Theravance Biopharma R&D IP, LLC

08/18/23

2D 3D TSV

34

ENPP1 inhibitors and their use for the treatment of cancer

THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

08/18/23

2D 3D TSV

647

Methods, compositions, and uses of novel FYN kinase inhibitors

Pathways Neuro Pharma, Inc.

08/18/23

2D 3D TSV

42

Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors

D. E. Shaw Research, LLC; Relay Therapeutics, Inc.

08/18/23

2D 3D TSV

94

Pyrazolyl derivatives useful as anti-cancer agents

NOVARTIS AG

08/18/23

2D 3D TSV

34

Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors

REVOLUTION MEDICINES, INC.

08/18/23

2D 3D TSV

143

Pyrimidinone derivatives as SHP2 antagonists

Merck Patent GmbH

08/18/23

2D 3D TSV

365

SOS1 inhibitors

MIRATI THERAPEUTICS, INC.

08/18/23

2D 3D TSV

9

Substituted bicyclic compounds

Bristol-Myers Squibb Company

08/18/23

2D 3D TSV

303

Thiadiazole IRAK4 inhibitors

Gilead Sciences, Inc.

08/18/23

2D 3D TSV

79

Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound

TAIHO PHARMACEUTICAL CO., LTD.

08/11/23

2D 3D TSV

100

Carboxamide-pyrimidine derivatives as SHP2 antagonists

Merck Patent GmbH

08/11/23

2D 3D TSV

42

HGNC:6943 992 990

Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors

Eil Therapeutics, Inc.

08/11/23

2D 3D TSV

264

HGNC:6190 6192 6193 12440

Fused pyrimidine pyridinone compounds as JAK inhibitors

THERAVANCE BIOPHARMA R&D IP, LLC

08/11/23

2D 3D TSV

318

Substituted benzamides

Hoffmann-La Roche Inc.

08/11/23

2D 3D TSV

15

HGNC:644 3528

2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament

Boehringer Ingelheim International GmbH

08/06/23

2D 3D TSV

234

6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors

Ajax Therapeutics, Inc.

08/06/23

2D 3D TSV

44

Compound having KDM5 inhibitory activity and pharmaceutical use thereof

ONO PHARMACEUTICAL CO., LTD.

08/06/23

2D 3D TSV

82

Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide

Boehringer Ingelheim International GmbH

08/06/23

2D 3D TSV

80

Heterocyclic compounds, preparation methods therefor, and methods of uses thereof

INVENTISBIO CO., LTD.

08/06/23

2D 3D TSV

101

Inhibitors of receptor interacting protein kinase I for the treatment of disease

Board of Regents, The University of Texas System

08/06/23

2D 3D TSV

93

Isoindoline compositions and methods for treating neurodegenerative disease

Cognition Therapeutics, Inc.

08/06/23

2D 3D TSV

21

HGNC:6190 9380 6192 6193 10251 11892 12440 10252 391 5960 9399 7794 9401 28858 9403

Isoquinoline-steroid conjugates and uses thereof

Aerie Pharmaceuticals, Inc.

08/06/23

2D 3D TSV

25

MAGL inhibitors

H. LUNDBECKA/S

08/06/23

2D 3D TSV

25

Macrocyclic immunomodulators

CHEMOCENTRYX, INC.

08/06/23

2D 3D TSV

51

Macrocyclic indoles as Mcl-1 inhibitors

ASCENTAGE PHARMA (SUZHOU) CO., LTD.; THE REGENTS OF THE UNIVERSITY OF MICHIGAN; ASCENTAGE PHARMA GROUP CORP LIMITED

08/06/23

2D 3D TSV

1

Method for preparing pyrrolidinyl urea derivative

ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.

08/06/23

2D 3D TSV

24

Naphthyridinone compounds as JAK2 V617F inhibitors

Incyte Corporation

08/06/23

2D 3D TSV

51

Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors

ASTRAZENECA AB

08/06/23

2D 3D TSV

96

Pyridazinones as PARP7 inhibtors

Ribon Therapeutics, Inc.

08/06/23

2D 3D TSV

217

Therapeutic compounds and compositions

EXITHERA PHARMACEUTICALS, INC.

08/06/23

2D 3D TSV

121

ATM kinase inhibitors and compositions and methods of use thereof

CHDI Foundation, Inc.

07/31/23

2D 3D TSV

106

HGNC:17293 10431 6863

Azalactam compounds as HPK1 inhibitors

PFIZER INC.

07/31/23

2D 3D TSV

82

C5a receptor modulators

IDORSIA PHARMACEUTICALS LTD.

07/31/23

2D 3D TSV

123

CDK inhibitors and their use as pharmaceuticals

Prelude Therapeutics Incorporated

07/31/23

2D 3D TSV

14

HGNC:6161 6163

Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof

OcuTerra Therapeutics, Inc.

07/31/23

2D 3D TSV

245

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc.

07/31/23

2D 3D TSV

491

HGNC:5275 17933

MYST family histone acetyltransferase inhibitors

Epizyme, Inc.

07/31/23

2D 3D TSV

24

Pyridinone MK2 inhibitors and uses thereof

XINTHERA, INC.

07/31/23

2D 3D TSV

385

Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors

Dart Neuroscience, LLC

07/31/23

2D 3D TSV

138

Bicycloheptane pyrrolidine orexin receptor agonists

Merck Sharp & Dohme LLC

07/25/23

2D 3D TSV

37

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

AstraZeneca AB

07/25/23

2D 3D TSV

22

Compounds and compositions as protein kinase inhibitors

ARRAY BIOPHARMA INC.

07/25/23

2D 3D TSV

55

HGNC:6307 9967

Compounds useful as RET inhibitors

Cancer Research Technology Limited

07/25/23

2D 3D TSV

82

MK2 inhibitors and uses thereof

XINTHERA, INC.

07/25/23

2D 3D TSV

2

HGNC:8803 6342

Methods of treating disorders using CSF1R inhibitors

Deciphera Pharmaceuticals, LLC

07/25/23

2D 3D TSV

16

HGNC:9413 8975 3236

Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors

Mekanistic Therapeutics LLC

07/19/23

2D 3D TSV

155

5-membered and bicyclic heterocyclic amides as inhibitors of ROCK

Bristol-Myers Squibb Company

07/16/23

2D 3D TSV

40

Amino pyrimidine derivatives

Novartis AG

07/16/23

2D 3D TSV

17

Bicyclic compounds as ATX inhibitors

Hoffmann-La Roche Inc.

07/16/23

2D 3D TSV

88

HGNC:1780 1771 1773

CDK inhibitors and their use as pharmaceuticals

Prelude Therapeutics Incorporated

07/16/23

2D 3D TSV

35

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

AstraZeneca AB

07/16/23

2D 3D TSV

11

Compounds for the treatment of kinase-dependent disorders

Exelixis, Inc.

07/16/23

2D 3D TSV

51

Heterocyclic compounds as immunomodulators

Incyte Corporation

07/16/23

2D 3D TSV

13

HGNC:4852 4854 4853

Histone deacetylase inhibitors for immunomodulation in tumor microenvironment

Great Novel Therapeutics Biotech & Medicals Corporation

07/16/23

2D 3D TSV

96

Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

Incyte Corporation

07/16/23

2D 3D TSV

303

HGNC:4617 3091

Isoquinolin-3-yl carboxamides and preparation and use thereof

BioSplice Therapeutics, Inc.

07/16/23

2D 3D TSV

12

Matrix metalloproteinase (MMP) inhibitors and methods of use thereof

Foresee Pharmaceuticals Co., Inc.

07/16/23

2D 3D TSV

21

HGNC:6190 6192 6193 12440

Pharmaceutical compounds

SAREUM LIMITED

07/16/23

2D 3D TSV

82

Polycyclic compounds as allosteric SHP2 inhibitors

REVOLUTION MEDICINES, INC.

07/16/23

2D 3D TSV

159

Pyridone amides as modulators of sodium channels

VERTEX PHARMACEUTICALS INCORPORATED

07/16/23

2D 3D TSV

7

Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

Olema Pharmaceuticals, Inc.

07/16/23

2D 3D TSV

50

4-substitued cytisine analogues

TBA

07/09/23

2D 3D TSV

7

Antibody-drug conjugates comprising a cyclic dinucleotide

Takeda Pharmaceutical Company Limited

07/09/23

2D 3D TSV

37

HGNC:3690 3691 3689 3688

Bicyclic heterocycles as FGFR4 inhibitors

Incyte Corporation; Incyte Holdings Corporation

07/09/23

2D 3D TSV

36

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

AstraZeneca AB

07/09/23

2D 3D TSV

378

HGNC:4849 4848

Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Janssen Pharmaceutica NV

07/09/23

2D 3D TSV

56

HGNC:3691 3688

FGFR4 inhibitor, preparation method therefor, and applications thereof

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.; Shanghai Hansoh Biomedical Co., Ltd.

07/09/23

2D 3D TSV

11

HGNC:6190 6192 6193 12440

Fused imidazo-piperidine JAK inhibitors

Theravance Biopharma R&D IP, LLC

07/09/23

2D 3D TSV

148

Granzyme B directed imaging and therapy

CytoSite Biopharma Inc.

07/09/23

2D 3D TSV

65

Inhibitors of RAF kinases

KINNATE BIOPHARMA INC.

07/09/23

2D 3D TSV

204

MCL1 inhibitors

Gilead Sciences, Inc.

07/09/23

2D 3D TSV

97

Methods of treating intraocular pressure with activators of Tie-2

EyePoint Pharmaceuticals, Inc.

07/09/23

2D 3D TSV

80

RIP1K inhibitors

Rigel Pharmaceuticals, Inc.

07/09/23

2D 3D TSV

206

Therapeutically active compounds and their methods of use

Servier Pharmaceuticals LLC

07/09/23

2D 3D TSV

86

HGNC:6307 9967

Heterocyclic compounds as RET kinase inhibitors

Cancer Research Technology Limited

07/03/23

2D 3D TSV

496

Imidazole-containing inhibitors of ALK2 kinase

BioCryst Pharmaceuticals, Inc.

07/03/23

2D 3D TSV

18

Tetrazole derivatives as TRPA1 inhibitors

Boehringer Ingelheim International GmbH

07/03/23

2D 3D TSV

8

Thienopyrrole compounds

Gilead Sciences, Inc.

07/03/23

2D 3D TSV

26

Tricyclic urea compounds as JAK2 V617F inhibitors

Incyte Corporation

07/03/23

2D 3D TSV

54

Benzimidazole derivative compounds and uses thereof

Pfizer Inc.

07/02/23

2D 3D TSV

13

MASP-2 inhibitors and methods of use

OMEROS CORPORATION

07/02/23

2D 3D TSV

129

HGNC:4849 4848

Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists

CHRONOS THERAPEUTICS LIMITED

07/02/23

2D 3D TSV

28

Treatment of Rett syndrome

Cold Spring Harbor Laboratory

07/02/23

2D 3D TSV

87

Tricyclic compounds as histone methyltransferase inhibitors

Global Blood Therapeutics, Inc.

07/02/23

2D 3D TSV

170

HGNC:171 1076 172 175

ALK2 inhibitors and methods for inhibiting BMP signaling

The Brigham and Women''s Hospital, Inc.; The United States of America, as Represented by the Secretary, Dept. of Health and Human Services

06/26/23

2D 3D TSV

4

HGNC:6190 6192 6193 12440

Aminopyrimidinyl derivatives

Pfizer Inc.

06/26/23

2D 3D TSV

37

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

AstraZeneca AB

06/26/23

2D 3D TSV

32

HGNC:11283 427 3432 8803 3763 3430 6307 8804 5465 76 3690 3691 6342 3689 6873 3236 7029 9967 3688 2731

Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof

Shanghai Institute Of Material Medica, Chinese Academy of Sciences

06/26/23

2D 3D TSV

4

Glucagon-like peptide1 receptor agonists

Eli Lilly and Company

06/26/23

2D 3D TSV

23

Indolizine derivatives and their application in medicine

KIND PHARMACEUTICAL

06/26/23

2D 3D TSV

252

HGNC:3553 17038

Pyrazole MAGL inhibitors

H. LUNDBECK A/S

06/26/23

2D 3D TSV

32

Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists

HOFFMANN-LA ROCHE INC.; EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

06/26/23

2D 3D TSV

6

Substituted piperazines as BTK inhibitors

HUTCHISON MEDIPHARMA LIMITED

06/26/23

2D 3D TSV

8

HGNC:5383 5382

7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors

Eli Lilly and Company

06/19/23

2D 3D TSV

98

HGNC:8978 9413 8975 3942 8974 8977 8976

Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease

Petra Pharma Corporation

06/19/23

2D 3D TSV

8

Amide compounds for treatment of immune and inflammatory disorders

Achillion Pharmaceuticals, Inc.

06/19/23

2D 3D TSV

81

C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

The United States of America, as represented by the Secretary, Department of Health and Human Services; Pontificia Universidad Catolica de Chile

06/19/23

2D 3D TSV

18

Compound as mTOR inhibitor and use thereof

MEDICINAL BIOCONVERGENCE RESEARCH CENTER; INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

06/19/23

2D 3D TSV

18

HGNC:6833 6834 550

Halo-allylamine SSAO/VAP-1 inhibitor and use thereof

NANJING TRANSTHERA BIOSCIENCES CO., LTD.

06/19/23

2D 3D TSV

663

Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same

1ST Biotherapeutics, Inc.

06/19/23

2D 3D TSV

113

Oxadiazaspiro compounds for the treatment of drug abuse and addiction

ESTEVE PHARMACEUTICALS, S.A.

06/19/23

2D 3D TSV

2

HGNC:2637 2625

Pan-tropic entry inhibitors

Emory University

06/19/23

2D 3D TSV

14

HGNC:6190 6192

Pyrazolochlorophenyl compounds, compositions and methods of use thereof

Genentech, Inc.

06/19/23

2D 3D TSV

50

Selective androgen receptor degrader (SARD) ligands and methods of use

University of Tennessee Research Foundation

06/19/23

2D 3D TSV

111

Substituted 4-phenylpiperidines, their preparation and use

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

06/19/23

2D 3D TSV

228

Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition

Optikira LLC; The Regents of the University of California

06/19/23

2D 3D TSV

814

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

Array Biopharma Inc.

06/19/23

2D 3D TSV

327

Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling

Kumquat Biosciences Inc.

06/19/23

2D 3D TSV

2

HGNC:5294 5291 5302 3026 5301 3023 5289 5300 5287 5286 5297 3020 262 263 264

5-HT2A agonists for use in treatment of depression

LOPHORA APS

06/11/23

2D 3D TSV

156

HGNC:6190 6192 6193 13575 1103 1105 1104

BRD4-kinase inhibitors as cancer therapeutics

H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

06/11/23

2D 3D TSV

8

Compounds for degrading Tau protein aggregates and uses thereof

APRINOIA THERAPEUTICS LIMITED

06/11/23

2D 3D TSV

9

Derivatives of 4-aminoantipyrine as anti-Alzheimers butyrylcholinesterase inhibitors

TBA

06/11/23

2D 3D TSV

11

GLP-1 receptor agonist and use thereof

ILDONG PHARMACEUTICAL CO., LTD.

06/11/23

2D 3D TSV

443

MCL-1 inhibitors

Gilead Sciences, Inc.

06/11/23

2D 3D TSV

10

HGNC:8153 8154 2637 8156 2625 2623

Polypeptide compound, pharmaceutical composition, preparation method and application thereof

CHENGDU SINTANOVO BIOTECHNOLOGY CO., LTD.

06/11/23

2D 3D TSV

31

HGNC:1780 1772 1771 1778 1722 1774 1773 1775

Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors

G1 Therapeutics, Inc.

06/11/23

2D 3D TSV

46

Substituted benzene compounds

Epizyme, Inc.

06/11/23

2D 3D TSV

144

Tetrahydrobenzofurodiazepinone compound and pharmaceutical use thereof

Japan Tobacco Inc.

06/11/23

2D 3D TSV

155

Amino acid compounds and methods of use

Pliant Therapeutics, Inc.

06/02/23

2D 3D TSV

192

HGNC:8775 8774 8776

Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines

H. Lundbeck A/S

06/02/23

2D 3D TSV

78

Compounds for the treatment of BRAF-associated diseases and disorders

Array BioPharma Inc.

06/02/23

2D 3D TSV

18

HGNC:1925 16627

Diazaindole derivative and use thereof as CHK1 inhibitor

MEDSHINE DISCOVERY INC.

06/02/23

2D 3D TSV

12

HGNC:6190 6192 6193 12440

Dimethyl amino azetidine amides as JAK inhibitors

THERAVANCE BIOPHARMA R&D IP, LLC

06/02/23

2D 3D TSV

48

HGNC:10593 10585 10596

Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

TBA

06/02/23

2D 3D TSV

103

HGNC:9886 17071 18039

Histone demethylase inhibitors

CELGENE QUANTICEL RESEARCH, INC

06/02/23

2D 3D TSV

124

Pharmaceutical compounds

PFIZER INC.

06/02/23

2D 3D TSV

93

Pyrazoles

JANSSEN PHARMACEUTICALS, INC.

06/02/23

2D 3D TSV

22

Selective estrogen receptor degraders

Eli Lilly and Company

06/02/23

2D 3D TSV

53

Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Pfizer Inc.

06/02/23

2D 3D TSV

99

HGNC:17432 1936 6251

Substituted amino triazoles useful as chitinase inhibitors

Molecure S.A.

06/02/23

2D 3D TSV

14

Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors

LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD.; SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.; MEDSHINE DISCOVERY INC.

06/02/23

2D 3D TSV

17

6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Sprint Bioscience AB

06/01/23

2D 3D TSV

21

Compounds and methods useful for treating or preventing cancers

THE BROAD INSTITUTE, INC.; DANA-FARBER CANCER INSTITUTE, INC.

06/01/23

2D 3D TSV

253

Compounds which are inhibitors of Notum

UCL Business LTD

06/01/23

2D 3D TSV

9

HGNC:6263 6255 6256 6257 6259

Method for controlling hematophagous or sap-feeding arthropods

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

06/01/23

2D 3D TSV

313

HGNC:8153 8154 8156

Opioid receptor modulators

EPIODYNE, INC.

06/01/23

2D 3D TSV

90

Selective D3 dopamine receptor agonists and methods of their use

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; THE UNIVERSITY OF KANSAS; THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

06/01/23

2D 3D TSV

19

Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor

SUMITOMO PHARMA CO., LTD.

06/01/23

2D 3D TSV

260

Sulfonamide compound or salt thereof

Taiho Pharmaceutial Co., Ltd.

06/01/23

2D 3D TSV

14

HGNC:5383 5382

7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors

Eli Lilly and Company

05/27/23

2D 3D TSV

39

Lymphoid-specific tyrosine phosphatase (LYP) inhibitors

Purdue Research Foundation

05/27/23

2D 3D TSV

111

SHP2 phosphatase inhibitors and methods of use thereof

D. E. Shaw Research, LLC; Relay Therapeutics, Inc.

05/27/23

2D 3D TSV

46

Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity

PRAXIS PRECISION MEDICINES, INC.

05/27/23

2D 3D TSV

57

Substituted pyridine derivatives as SARM1 inhibitors

NURA BIO, INC.

05/27/23

2D 3D TSV

32

HGNC:934 933

Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity

SHIONOGI & CO., LTD.

05/27/23

2D 3D TSV

21

HGNC:268 262 263 264

Triazolo-pyrimidine compounds and uses thereof

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

05/27/23

2D 3D TSV

223

Indole carboxamide compounds

Bristol-Myers Squibb Company

05/22/23

2D 3D TSV

2

Method of treatment with histamine-3 receptor inverse agonist

SUVEN LIFE SCIENCES LIMITED

05/22/23

2D 3D TSV

4

HGNC:30185 2717

Protein degraders and uses thereof

KYMERA THERAPEUTICS, INC.

05/22/23

2D 3D TSV

15

Spirocyclic compounds

C4 Therapeutics, Inc.

05/22/23

2D 3D TSV

19

Uracil compound as c-MET/AXL inhibitor

MEDSHINE DISCOVERY, INC.

05/22/23

2D 3D TSV

20

6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use

Purdue Research Foundation

05/11/23

2D 3D TSV

1532

Aminopyrrolotriazines as kinase inhibitors

Bristol-Myers Squibb Company

05/11/23

2D 3D TSV

186

Benzoimidazoles as prolyl hydroxylase inhibitors

Janssen Pharmaceutica NV

05/11/23

2D 3D TSV

18

Compounds active towards nuclear receptors

NUEVOLUTION A/S

05/10/23

2D 3D TSV

19

Heterocyclic compounds as immunomodulators

Incyte Corporation

05/10/23

2D 3D TSV

36

Oxysterols and methods of use thereof

SAGE THERAPEUTICS, INC.

05/10/23

2D 3D TSV

83

Substituted pyridotriazine compounds and uses thereof

Gilead Sciences, Inc.

05/10/23

2D 3D TSV

24

3-triazolyl methyl-1,3,5-triazine-2,4-dione compounds and preparation method and application thereof

SHAANXI PANLONG PHARMACEUTICAL CO., LTD.

05/09/23

2D 3D TSV

302

8-aminoisoquinoline compounds and uses thereof

Genentech, Inc.

05/09/23

2D 3D TSV

116

HGNC:6371 3529 6357

Enzyme inhibitors

KalVista Pharmaceuticals Limited

05/09/23

2D 3D TSV

123

Glycosidase inhibitors

Asceneuron SA

05/09/23

2D 3D TSV

167

Inhibitors of RHO associated coiled-coil containing protein kinase

Kadmon Corporation, LLC

05/09/23

2D 3D TSV

10

Pharmaceutical formulations comprising CCR3 antagonists

Alkahest, Inc.

05/09/23

2D 3D TSV

62

Substituted condensed thiophenes as modulators of sting

CTXT PTY LIMITED

05/09/23

2D 3D TSV

22

HGNC:10251 27972 26249

Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and method for performing an in vivo related application that benefits from the inhibition of a kinase

INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

05/05/23

2D 3D TSV

106

Bicyclic amide compounds and methods of use thereof

Genentech, Inc.

05/05/23

2D 3D TSV

9

HGNC:7175 7176 7166 7159

Curcumin analogues as zinc chelators and their uses

THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK; CHEM-MASTER INTERNATIONAL INC.

05/05/23

2D 3D TSV

42

HGNC:3691 3688

FGFR4 inhibitor and preparation method and use thereof

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.; Shanghai Hansoh Biomedical Co., Ltd.

05/05/23

2D 3D TSV

40

Heterocyclic compounds as immunomodulators

Incyte Corporation

05/05/23

2D 3D TSV

138

HGNC:8978 795 8975 3942 8977 8976

Imidazolonylquinolines and the use thereof as ATM kinase inhibitors

Merck Patent GmbH

05/05/23

2D 3D TSV

161

HGNC:6833 6834 2671 6666

Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

05/05/23

2D 3D TSV

93

Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors

Hoffmann-La Roche Inc.

05/05/23

2D 3D TSV

5

HGNC:8795 8774

PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases

H. Lundbeck A/S

05/05/23

2D 3D TSV

19

Compounds and therapeutic uses thereof

VioGen Biosciences, LLC

04/30/23

2D 3D TSV

64

HGNC:3711 3721

MTORC1 modulators and uses thereof

Aeovian Pharmaceuticals, Inc.

04/30/23

2D 3D TSV

285

PCSK9 inhibitors and methods of use thereof

AstraZeneca AB

04/30/23

2D 3D TSV

34

Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors

Array BioPharma Inc.

04/30/23

2D 3D TSV

19

Compounds and compositions for the treatment of parasitic diseases

Novartis AG

04/23/23

2D 3D TSV

53

Cyclic dinucleotides as sting agonists

Janssen Biotech, Inc.

04/23/23

2D 3D TSV

10

Enhancing CD8+ T cells for adoptive T cell therapy by inhibiting PTPN1 (PTP1B) and PTPN2 (TC-PTP)

THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY

04/23/23

2D 3D TSV

26

JAK1 pathway inhibitors for the treatment of gastrointestinal disease

Incyte Corporation

04/23/23

2D 3D TSV

427

Monoacylglycerol lipase modulators

Janssen Pharmaceutica NV

04/23/23

2D 3D TSV

20

PD-L1/STING conjugates and methods of use

Incyte Corporation

04/23/23

2D 3D TSV

4

Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders

MINDSET PHARMA INC.

04/23/23

2D 3D TSV

3

SHP2 inhibitor compositions and methods for treating cancer

Revolution Medicines, Inc.

04/23/23

2D 3D TSV

719

Substituted indole Mcl-1 inhibitors

Vanderbilt University

04/23/23

2D 3D TSV

28

HGNC:992 990

Benzamide compounds

Recurium IP Holdings, LLC

04/14/23

2D 3D TSV

26

Bicyclic heterocycles as FGFR inhibitors

Incyte Corporation

04/14/23

2D 3D TSV

13

Bipyrazole derivatives as JAK inhibitors

Incyte Corporation

04/14/23

2D 3D TSV

27

Certain chemical compositions and methods of use thereof

Algen Biotechnologies, Inc.

04/14/23

2D 3D TSV

164

Compounds, compositions, and methods

Denali Therapeutics Inc.

04/14/23

2D 3D TSV

46

Heterocyclic compound, application thereof and pharmaceutical composition comprising same

SUZHOU SINOVENT PHARMACEUTICALS CO., LTD.

04/14/23

2D 3D TSV

26

HGNC:8803 8804 6342

Highly active CSF1R inhibitor compound

XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.

04/14/23

2D 3D TSV

25

Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof

HINOVA PHARMACEUTICALS INC.

04/14/23

2D 3D TSV

40

HGNC:3356 3357

Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof

STINGRAY THERAPEUTICS, INC.

04/14/23

2D 3D TSV

73

Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof

Pharmablock Sciences (Nanjing), Inc.

04/14/23

2D 3D TSV

14

Oxazolidinone antibiotic compounds and process of preparation

BUGWORKS RESEARCH, INC.

04/14/23

2D 3D TSV

99

HGNC:270 272

PARP1 inhibitors and uses thereof

XINTHERA, INC.

04/14/23

2D 3D TSV

3

Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders

Mindset Pharma Inc.

04/14/23

2D 3D TSV

144

HGNC:7027 12446

Pyrrolotriazine compounds as TAM inhibitors

Incyte Corporation

04/14/23

2D 3D TSV

51

Small molecule inducers of autophagy

Board of Regents, The University of Texas System

04/14/23

2D 3D TSV

514

Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors

D. E. Shaw Research, LLC; Relay Therapeutics, Inc.

04/14/23

2D 3D TSV

4

HGNC:6251 14299

Amino alcohol derivative, pharmaceutical composition and application thereof

BEIJING FORELAND PHARMA CO., LTD.

04/09/23

2D 3D TSV

15

Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof

SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

04/09/23

2D 3D TSV

6

Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia

STEALTH BIOTHERAPEUTICS INC.

04/09/23

2D 3D TSV

13

HGNC:17663 16490 18648 3590 3009 14892

Dash inhibitors, and uses related thereto

Trustees of Tufts College

04/09/23

2D 3D TSV

165

HGNC:3650 3437

Dihydrothieno[3,2-b]pyridine compounds

IDEAYA BIOSCIENCES, INC.

04/09/23

2D 3D TSV

33

Heterocyclic compounds as BET inhibitors

NUVATION BIO INC.

04/09/23

2D 3D TSV

27

Inhibitors of EGFR and methods of use thereof

Dana-Farber Cancer Institute, Inc.

04/09/23

2D 3D TSV

479

MASP-2 inhibitors and methods of use

OMEROS CORPORATION

04/09/23

2D 3D TSV

22

Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

Heptares Therapeutics Limited

04/09/23

2D 3D TSV

57

RIP1K inhibitors

Rigel Pharmaceuticals, Inc.

04/09/23

2D 3D TSV

2

HGNC:3530 6371 9475 3529 3535 6357 9071

Solid forms of a plasma kallikrein inhibitor and salts thereof

KalVista Pharmaceuticals Limited

04/09/23

2D 3D TSV

80

Spirocyclic compounds

C4 Therapeutics, Inc.

04/09/23

2D 3D TSV

225

Substituted pyridopyrimidinonyl compounds useful as T cell activators

TBA

04/09/23

2D 3D TSV

145

Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors

VENENUM BIODESIGN, LLC

04/09/23

2D 3D TSV

73

Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors

Boehringer Ingelheim International GmbH

04/09/23

2D 3D TSV

21

Compounds useful as immunomodulators

Bristol-Myers Squibb Company

03/31/23

2D 3D TSV

227

Condensed ring compounds having dopamine D3 receptor antagonistic effect

Shionogi & Co., Ltd.

03/31/23

2D 3D TSV

289

Fluoroalkyl-oxadiazoles and uses thereof

Tenaya Therapeutics, Inc.

03/31/23

2D 3D TSV

22

Heterocyclic RIP1 inhibitory compounds

Rigel Pharmaceuticals, Inc.

03/31/23

2D 3D TSV

3

HGNC:6192 12440

Heterocyclic compounds for inhibiting TYK2 activities

Beijing Innocare Pharma Tech Co.

03/31/23

2D 3D TSV

20

Inhibiting mutant IDH-1

FORMA Therapeutics, Inc.

03/31/23

2D 3D TSV

282

Inhibitors of LRRK2 kinase

HALIA THERAPEUTICS, INC.

03/31/23

2D 3D TSV

72

Spiro-oxazolones

Hoffmann-La Roche Inc.

03/31/23

2D 3D TSV

64

Therapeutic agent for non-motor symptoms associated with Parkinson's disease

Sumitomo Pharma Co., Ltd.

03/31/23

2D 3D TSV

23

Thienopyrimidones

Boehringer Ingelheim International GmbH

03/31/23

2D 3D TSV

29

HGNC:3690 3691 3689 3688

Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof

Beijing Innocare Pharma Tech Co., Ltd.

03/26/23

2D 3D TSV

44

Antibacterial agents: arylalkylcarboxamido phloroglucinols

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

03/26/23

2D 3D TSV

4

HGNC:13575 1103 1105 1104

BRD4 inhibitor

HINOVA PHARMACEUTICALS INC.

03/26/23

2D 3D TSV

14

Cyanoaryl-aniline compounds for treatment of dermal disorders

NFLECTION THERAPEUTICS, INC.

03/26/23

2D 3D TSV

40

Heterocyclic compounds as immunomodulators

Incyte Corporation

03/26/23

2D 3D TSV

26

HGNC:11708 6059

Inhibitor of indoleamine 2,3-dioxygenase-1 and methods of manufacture and use thereof

University Health Network

03/26/23

2D 3D TSV

171

HGNC:4852 4854 4853

Inhibitors of histone deacetylase

The General Hospital Corporation; The Broad Institute, Inc.; Massachusetts Institute of Technology

03/26/23

2D 3D TSV

452

N-cyano-7-azanorbornane derivatives and uses thereof

AMGEN INC.

03/26/23

2D 3D TSV

38

HGNC:262 263 264

Pyrazine compounds and uses thereof

DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

03/26/23

2D 3D TSV

73

Pyrrolo[1,2-b]pyridazine derivatives

Gilead Sciences, Inc.

03/26/23

2D 3D TSV

69

HGNC:3690 3691 3689 3688

Bicyclic heterocycles as FGFR inhibitors

Incyte Corporation

03/20/23

2D 3D TSV

4

Heterocyclic compounds as immunomodulators

Incyte Corporation

03/20/23

2D 3D TSV

2

Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)

FORMA Therapeutics, Inc.

03/20/23

2D 3D TSV

39

HGNC:1925 6251

5-heteroaryl-1H-pyrazol-3-amine derivative

Sumitomo Pharma Co., Ltd.

03/19/23

2D 3D TSV

158

5-membered heteroaryl carboxamide compounds for treatment of HBV

Assembly Biosciences, Inc.

03/19/23

2D 3D TSV

145

Amino acid compounds and methods of use

Pliant Therapeutics, Inc.

03/19/23

2D 3D TSV

70

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

Enanta Pharmaceuticals, Inc.

03/19/23

2D 3D TSV

17

Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease

Board of Regents, The University of Texas System

03/19/23

2D 3D TSV

158

HGNC:2160 2159

Cannabinoid receptor type 2 (CB2) modulators and uses thereof

Teon Therapeutics, Inc.

03/19/23

2D 3D TSV

50

HGNC:16490 18648 3590 3009 9358 14892

Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists

Trustees of Tufts College

03/19/23

2D 3D TSV

487

Compounds and uses thereof

Foghorn Therapeutics Inc.

03/19/23

2D 3D TSV

4

Compounds for use as inhibitors of alternative oxidase or cytochrome bc1 complex

AlternOx Scientific Limited

03/19/23

2D 3D TSV

62

HGNC:5253 1735

Fused amino pyridine as HSP90 inhibitors

Guris, Inc.

03/19/23

2D 3D TSV

377

Indole compounds and analogues thereof

BioCryst Pharmaceuticals, Inc.

03/19/23

2D 3D TSV

373

Isoquinolines as inhibitors of HPK1

Genentech, Inc.

03/19/23

2D 3D TSV

17

Morpholinylpyridone compounds

Sprint Bioscience AB

03/19/23

2D 3D TSV

175

Proteasome activity enhancing compounds

Proteostasis Therapeutics, Inc.

03/19/23

2D 3D TSV

22

RIP1 inhibitory compounds and methods for making and using the same

Rigel Pharmaceuticals, Inc.

03/19/23

2D 3D TSV

718

HGNC:7989 6407

Ras inhibitors

Revolution Medicines, Inc.

03/19/23

2D 3D TSV

149

Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors

Pfizer Inc.

03/19/23

2D 3D TSV

17

2-(substituted benzene matrix) aromatic formate FTO inhibitor, preparation method therefor, and applications thereof

SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

03/12/23

2D 3D TSV

474

ACLY inhibitors and uses thereof

Nimbus Artemis, Inc.

03/12/23

2D 3D TSV

98

HGNC:10251 10252

Amide compounds as kinase inhibitors, compositions and methods of treatment

Translational Drug Development LLC

03/12/23

2D 3D TSV

215

HGNC:6735 1133 6171 11719 3236 6524

Bruton's tyrosine kinase inhibitors

SUZHOU BAIJIBUGONG PHARMACEUTICAL TECHNOLOGY CO., LTD.

03/12/23

2D 3D TSV

656

PD-1/PD-L1 inhibitors

Gilead Sciences, Inc.

03/12/23

2D 3D TSV

22

Phosphonate linkers and their use to facilitate cellular retention of compounds

Merck Sharp & Dohme LLC

03/12/23

2D 3D TSV

59

Potent and selective inhibitors of monoamine transporters; method of making; and use thereof

THE USA, AS REPRESENTED BY THE SECRETARY, DHHS

03/12/23

2D 3D TSV

46

HGNC:934 2529 933

Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use

Amgen Inc.

03/06/23

2D 3D TSV

21

Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers

Jazz Pharmaceuticals Ireland Limited

03/06/23

2D 3D TSV

109

HGNC:6307 9967

Heterocyclic compounds as RET kinase inhibitors

Cancer Research Technology Limited

03/06/23

2D 3D TSV

137

HGNC:3430 3236

Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof

BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED

03/06/23

2D 3D TSV

23

Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections

Gilead Sciences, Inc.

03/06/23

2D 3D TSV

581

Transglutaminase 2 (TG2) inhibitors

Sitari Pharma, Inc.

03/06/23

2D 3D TSV

80

Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same

LegoChem Biosciences, Inc.

03/05/23

2D 3D TSV

822

HPK1 antagonists and uses thereof

Nimbus Saturn, Inc.

03/05/23

2D 3D TSV

523

HGNC:8978 8975 3942 8977 8976

Heterocyclic compounds and uses thereof

MILLENNIUM PHARMACEUTICALS, INC.

03/05/23

2D 3D TSV

238

Isoquinolin-3-yl carboxamides and preparation and use thereof

BioSplice Therapeutics, Inc.

03/05/23

2D 3D TSV

45

Kinase inhibitor compounds and compositions and methods of use

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

03/05/23

2D 3D TSV

9

LSD1 inhibitors and medical uses thereof

Constellation Pharmaceuticals, Inc.

03/05/23

2D 3D TSV

59

Neprilysin inhibitors

THERAVANCE BIOPHARMA R&D IP, LLC

03/05/23

2D 3D TSV

13

HGNC:2594 2593 2637 2625 2623

Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1

MANGOSUTHU UNIVERSITY OF TECHNOLOGY

03/05/23

2D 3D TSV

31

Therapeutic compounds and methods of use thereof

LIGATURE THERAPEUTICS PTE. LTD.

03/05/23

2D 3D TSV

5

Amide compound having bet proteolysis-inducing action and medicinal application thereof

MITSUBISHI TANABE PHARMA CORPORATION

02/26/23

2D 3D TSV

47

HGNC:1133 3236

BTK inhibitor compounds

Eli Lilly and Company

02/26/23

2D 3D TSV

10

HGNC:6307 3690 3691 3689 3688

Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer

Janssen Pharmaceutica NV

02/26/23

2D 3D TSV

230

Compositions and methods for treating CNS disorders

Sage Therapeutics, Inc.

02/26/23

2D 3D TSV

6

HGNC:6367 6357 9071

Compounds and compositions for the treatment of neurodegenerative and inflammatory diseases

SARBONNE UNIVERSITE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE; ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS; INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE; UNIVERSITÉ DE MONTPELLIER; ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER

02/26/23

2D 3D TSV

65

Compounds for the treatment of kinase-dependent disorders

Exelixis, Inc.

02/26/23

2D 3D TSV

25

Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease

SHY Therapeutics LLC

02/26/23

2D 3D TSV

108

HGNC:8978 8975 8977 8976

Heterocyclic compounds and uses thereof

Infinity Pharmaceuticals, Inc.

02/26/23

2D 3D TSV

6

HGNC:6112 17967

IRAK degraders and uses thereof

DANA-FARBER CANCER INSTITUTE, INC.

02/26/23

2D 3D TSV

27

Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors

UNIVERSISITY OF UTAH RESEARCH FOUNDATION

02/26/23

2D 3D TSV

42

Phenothiazine derivatives and uses thereof

CAMP4 THERAPEUTICS CORPORATION

02/26/23

2D 3D TSV

126

Pyrazolopyrimidine compounds and uses thereof

Incyte Corporation

02/26/23

2D 3D TSV

5

HGNC:6112 17967

Quinoline compounds as IRAK inhibitors and uses thereof

Merck Patent GmbH

02/26/23

2D 3D TSV

17

STK19 inhibitors for treatment of cancer

TRUSTEES OF BOSTON UNIVERSITY; XIAMEN UNIVERSITY

02/26/23

2D 3D TSV

46

Sting modulator compounds, and methods of making and using

Takeda Pharmaceutical Company Limited

02/26/23

2D 3D TSV

51

HGNC:11305 7989 1057 8804 1778 6112 17967 9967 6524

Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors

CHILDREN''S HOSPITAL MEDICAL CENTER; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES

02/26/23

2D 3D TSV

96

Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors

AURIGENE DISCOVERY TECHNOLOGIES LIMITED

02/26/23

2D 3D TSV

71

HGNC:4852 6251 4854 4853

Substituted piperazines as selective HDAC1,2 inhibitors

REGENACY PHARMACEUTICALS, LLC

02/26/23

2D 3D TSV

1

Substituted piperidines as BTK inhibitors

HAISCO PHARMACEUTICALS PTE. LTD.

02/26/23

2D 3D TSV

8

Synthesis of peptide borate ester compound and use thereof

JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD.

02/26/23

2D 3D TSV

5

HGNC:3528 3529 3544

Tetrahydroisoquinoline derivatives, preparation process and use thereof

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

02/26/23

2D 3D TSV

94

Therapeutic compounds and methods of use thereof

Agency for Science, Technology and Research (A*STAR)

02/26/23

2D 3D TSV

16

HGNC:4584 8157

Analogs of dextromethorphan with balanced receptor activities

Center for Neurologic Study

02/20/23

2D 3D TSV

11

Benzisoxazole derivative

Sumitomo Pharma Co., Ltd.

02/20/23

2D 3D TSV

155

Dihydropyrrolopyridine inhibitors of ROR-gamma

Vitae Pharmaceuticals, LLC

02/20/23

2D 3D TSV

15

HGNC:3526 3527

Dioxoloisoquinolinone derivatives and use thereof

HANMI PHARMACEUTICAL CO., LTD.

02/20/23

2D 3D TSV

287

Heterobicyclic amides as inhibitors of CD38

Ribon Therapeutics, Inc.

02/20/23

2D 3D TSV

21

Heterocyclic compounds as immunomodulators

Incyte Corporation

02/20/23

2D 3D TSV

26

HGNC:4852 14064 19086 13315

Histone deacetylases (HDACs) inhibitors

AnnJi Pharmaceutical Co., Ltd.

02/20/23

2D 3D TSV

115

Histone demethylase inhibitors

CELGENE QUANTICEL RESEARCH, INC

02/20/23

2D 3D TSV

100

HGNC:4852 14065 14064 19086 14063 14068 14067 13315 4854 4853 18128

Isoindolines as HDAC inhibitors

Valo Health, Inc.

02/20/23

2D 3D TSV

198

MAP4K1 inhibitors

Blueprint Medicines Corporation

02/20/23

2D 3D TSV

39

Methods for treating depressive symptoms

ALKERMES PHARMA IRELAND LIMITED

02/20/23

2D 3D TSV

85

HGNC:8775 8774 8776

Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors

H. Lundbeck A/S

02/20/23

2D 3D TSV

10

Pyrrolo[1,2-b] pyridazine derivatives

Gilead Sciences, Inc.

02/20/23

2D 3D TSV

75

Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof

INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

02/20/23

2D 3D TSV

54

HGNC:3690 3689 3688

Bicyclic heterocycles as FGFR inhibitors

Incyte Holdings Corporation; Incyte Corporation

02/17/23

2D 3D TSV

228

Compositions and methods for treating CNS disorders

Sage Therapeutics, Inc.

02/17/23

2D 3D TSV

59

Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof

NURIX THERAPEUTICS, INC.

02/17/23

2D 3D TSV

382

Cyclic polypeptides for PCSK9 inhibition

Merck Sharp & Dohme LLC; Ra Pharmaceuticals, Inc.

02/17/23

2D 3D TSV

3

Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors

GENZYME CORPORATION

02/17/23

2D 3D TSV

17

Ligands to cereblon (CRBN)

DANA-FARBER CANCER INSTITUTE, INC.

02/17/23

2D 3D TSV

93

Naphthyridinone derivatives and their use in the treatment of arrhythmia

Novartis AG

02/17/23

2D 3D TSV

16

Small molecule inhibition of transcription factor SALL4 and uses thereof

DANA-FARBER CANCER INSTITUTE, INC.; THE BRIGHAM AND WOMEN''S HOSPITAL, INC.

02/17/23

2D 3D TSV

291

Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators

JANSSEN PHARMACEUTICA NV

02/17/23

2D 3D TSV

9

Use of known compounds as D-amino acid oxidase inhibitors

National Taiwan University; National Yang Ming Chiao Tung University; National Health Research Institutes

02/17/23

2D 3D TSV

431

2-(morpholin-4-yl)-1,7-naphthyridines

Bayer Pharma Aktiengesellschaft

02/16/23

2D 3D TSV

30

Alpha-5 beta-1 inhibitors

The Regents of the University of California; Shanghai ChemPartner Co., Ltd.

02/16/23

2D 3D TSV

45

HGNC:6866 30765

Analogs for the treatment of disease

Insilico Medicine IP Limited

02/16/23

2D 3D TSV

45

HGNC:6866 30765

Analogs for the treatment of disease

Insilico Medicine IP Limited

02/16/23

2D 3D TSV

63

Compositions and methods for treating infections

Vyera Pharmaceuticals, LLC

02/16/23

2D 3D TSV

31

Compounds

INFLAZOME LIMITED

02/16/23

2D 3D TSV

9

HGNC:549 6251

Imidazo[4,5-C]pyridine derived SSAO inhibitors

PROXIMAGEN, LLC

02/16/23

2D 3D TSV

123

Kinase inhibitors

The University of Manchester

02/16/23

2D 3D TSV

31

HGNC:3689 3688

Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists

Bristol-Myers Squibb Company

02/16/23

2D 3D TSV

17

Protacs targeting coronavirus 3CL protease and preparation method and application thereof

SHAANXI PANLONG PHARMACEUTICAL CO., LTD.

02/16/23

2D 3D TSV

51

SHP2 phosphatase inhibitors and methods of use thereof

Relay Therapeutics, Inc.; D. E. Shaw Research, LLC

02/16/23

2D 3D TSV

61

Use of aminomethylenecyclohexane-1,3-dione compound

WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD.

02/16/23

2D 3D TSV

717

Heterocyclic compound as a protein kinase inhibitor

HK inno.N Corporation

02/13/23

2D 3D TSV

14

HGNC:6190 6192 6193

JAK kinase inhibitor and preparation method and use thereof

SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD.

02/13/23

2D 3D TSV

31

Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)

Prelude Therapeutics, Incorporated

02/13/23

2D 3D TSV

7

HGNC:3430 3236

Alkyne substituted quinazoline compound and methods of use

Newgen Therapeutics, Inc.

02/12/23

2D 3D TSV

10

HGNC:6040 3236

Compounds for treating ILK-mediated diseases

The Cleveland Clinic Foundation

02/12/23

2D 3D TSV

1076

Indole and azaindole inhibitors of pad enzymes

Bristol-Myers Squibb Company

02/12/23

2D 3D TSV

310

Inhibitors of cysteine proteases and methods of use thereof

Pardes Biosciences, Inc.

02/12/23

2D 3D TSV

7

Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine

VTV THERAPEUTICS LLC

02/12/23

2D 3D TSV

15

Pyrazole compounds as LSD1 inhibitors and applications thereof

MEDSHINE DISCOVERY INC.

02/12/23

2D 3D TSV

58

CDPK1 inhibitors, compositions, and methods related thereto

Vyera Pharmaceuticals, LLC; Washington University

02/05/23

2D 3D TSV

11

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Kronos Bio, Inc.

02/05/23

2D 3D TSV

50

Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors

NIKANG THERAPEUTICS, INC.

02/05/23

2D 3D TSV

8

Inhibitors of DNMT1 as anticancer therapeutic agents

Victoria Link Limited; Albert Einstein College of Medicine

02/05/23

2D 3D TSV

15

MTOR inhibitor compounds

GALDERMA RESEARCH & DEVELOPMENT

02/05/23

2D 3D TSV

2

Macrocycle and composition comprising thereof

Shenzhen TargetRx, Inc.

02/05/23

2D 3D TSV

9

Protacs based on VHL ligand targeting coronavirus 3CL protease and preparation method and application thereof

SHAANXI PANLONG PHARMACEUTICAL CO., LTD.

02/05/23

2D 3D TSV

10

Radiolabeled pharmaceuticals and methods of making and using same

YALE UNIVERSITY

02/05/23

2D 3D TSV

370

Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction

ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)

02/05/23

2D 3D TSV

59

Compounds useful in HIV therapy

GlaxoSmithKline Intellectual Property Development Limited; The University of North Carolina at Chapel Hill; ViiV Healthcare Company

01/31/23

2D 3D TSV

50

Aminocyclobutanes as monoacylglycerol lipase modulators

Janssen Pharmaceutica NV

01/28/23

2D 3D TSV

250

Anti-tumor effect potentiator using novel biphenyl compound

Taiho Pharmaceutical Co., Ltd.

01/28/23

2D 3D TSV

16

HGNC:9617 6524

BRK inhibitory compound

ONO PHARMACEUTICAL CO., LTD.

01/28/23

2D 3D TSV

102

CRBN ligands and uses thereof

KYMERA THERAPEUTICS, INC.

01/28/23

2D 3D TSV

139

Compounds and methods for the enhanced degradation of targeted proteins

Arvinas Operations, Inc.; Yale University

01/28/23

2D 3D TSV

1

Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof

Shenzhen TargetRx, Inc.

01/28/23

2D 3D TSV

107

Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases

Takeda Pharmaceutical Company Limited

01/28/23

2D 3D TSV

35

2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy

THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING

01/21/23

2D 3D TSV

3

HGNC:2637 2625 2623

Aryl-piperidine derivatives

Artax Biopharma Inc.

01/21/23

2D 3D TSV

76

Azaspirocycles as monoacylglycerol lipase modulators

Janssen Pharmaceutica NV

01/21/23

2D 3D TSV

159

Compounds and methods for treating oxalate-related diseases

OxaluRx, Inc.

01/21/23

2D 3D TSV

138

Dihydroorotate dehydrogenase inhibitors

TBA

01/21/23

2D 3D TSV

19

HGNC:4852 14064 19086 14063 13315 4854 4853 18128

HDAC8 inhibitors for treating cancer

CITY OF HOPE; TAIPEI MEDICAL UNIVERSITY; ACADEMIA SINICA

01/21/23

2D 3D TSV

62

HGNC:17663 18648 3590 3009

Inhibitors of fibroblast activation protein

PRAXIS BIOTECH LLC

01/21/23

2D 3D TSV

81

SSAO inhibitor

TBA

01/21/23

2D 3D TSV

3

HGNC:3430 6307 8804 3236

Tetrahydroquinoline derivatives and a process of preparation thereof

KING ABDULAZIZ UNIVERSITY

01/21/23

2D 3D TSV

30

Therapeutic compounds and methods of use thereof

LIGATURE THERAPEUTICS PTE. LTD.

01/21/23

2D 3D TSV

196

HGNC:8775 8774 8776

1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

H. Lundbeck A/S

01/20/23

2D 3D TSV

150

ACLY inhibitors and uses thereof

Nimbus Artemis, Inc.

01/20/23

2D 3D TSV

45

Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases

Janssen Sciences Ireland Unlimited Company

01/20/23

2D 3D TSV

120

HGNC:5275 17933

Benzisoxazole sulfonamide derivatives

Pfizer Inc.; CTXT PTY LTD

01/20/23

2D 3D TSV

23

Cyclic dinucleotides as sting agonists

Janssen Biotech, Inc.

01/20/23

2D 3D TSV

24

Cyclic peptide immunomodulators

Bristol-Myers Squibb Company

01/20/23

2D 3D TSV

54

Indazole compounds and uses thereof

Incyte Corporation

01/20/23

2D 3D TSV

320

MTA-cooperative PRMT5 inhibitors

Mirati Therapeutics, Inc.

01/20/23

2D 3D TSV

66

N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors

Nerviano Medical Sciences S.R.L.

01/20/23

2D 3D TSV

7

HGNC:8153 8154 8156

Peptides for treatment of medical disorders

Humanwell Pharmaceutical US

01/20/23

2D 3D TSV

4

Therapeutic methods and combinations

TBA

01/20/23

2D 3D TSV

2

Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase

Hanmi Pharm. Co., Ltd.

01/20/23

2D 3D TSV

153

HGNC:8975 3942

Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways

Neuropore Therapies, Inc.

01/20/23

2D 3D TSV

26

Azaindolylpyridone and diazaindolylpyridone compounds

Sprint Bioscience AB

01/17/23

2D 3D TSV

38

Dopamine D2 receptor ligands

The Broad Institute, Inc.; Massachusetts Institute of Technology

01/17/23

2D 3D TSV

152

Pyrimidine-fused cyclic compound, preparation method therefor and application thereof

BLUERAY THERAPEUTICS (SHANGHAI) CO., LTD

01/17/23

2D 3D TSV

275

Tricyclic heterocycles as BET protein inhibitors

Incyte Corporation; Incyte Holdings Corporation

01/17/23

2D 3D TSV

368

Amido spirocyclic amide and sulfonamide derivatives

Valo Health, Inc.; Genentech, Inc.

01/06/23

2D 3D TSV

137

Compounds and methods useful in the treatment of a PRMT5-mediated disorder

ARGONAUT THERAPEUTICS LIMITED

01/06/23

2D 3D TSV

140

Compounds for inhibiting TNIK and medical uses thereof

KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

01/06/23

2D 3D TSV

127

Compounds for treatment of PD-L1 diseases

ChemoCentryx, Inc.

01/06/23

2D 3D TSV

2

HGNC:10251 10252

Deuterated compounds as rock inhibitors

Fochon Pharmaceuticals, Ltd.

01/06/23

2D 3D TSV

82

HGNC:8153 8154 8156

Mu opioid receptor modulators

The Regents of the University of California; Friedrich-Alexander-Universität Erlangen-Nürnberg; The Board of Trustees of the Leland Stanford Junior University; The University of North Carolina at Chapel Hill

01/06/23

2D 3D TSV

35

N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators

Boehringer Ingelheim International GmbH

01/06/23

2D 3D TSV

222

Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

MIRATI THERAPEUTICS, INC.

01/06/23

2D 3D TSV

121

Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors

KSQ Therapeutics, Inc.

01/06/23

2D 3D TSV

5

HGNC:2160 2159

Synthesis of (+)-cannabinoids and their therapeutic effects

SYMRISE AG

01/06/23

2D 3D TSV

222

2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor

HUTCHISON MEDIPHARMA LIMITED

12/30/22

2D 3D TSV

66

5-5 fused rings as C5a inhibitors

CHEMOCENTRYX, INC.

12/30/22

2D 3D TSV

6

5-aminolevulinate synthase inhibitors and methods of use thereof

University of South Florida

12/30/22

2D 3D TSV

486

Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors

CHEMOCENTRYX, INC.

12/30/22

2D 3D TSV

38

HGNC:9596 9595

EP4 antagonist

ONO PHARMACEUTICAL CO., LTD.

12/30/22

2D 3D TSV

49

Heterocyclic RIP1 kinase inhibitors

Rigel Pharmaceuticals, Inc.

12/30/22

2D 3D TSV

71

Inhibitors of Rho associated coiled-coil containing protein kinase

Kadmon Corporation, LLC

12/30/22

2D 3D TSV

321

MTA-cooperative PRMT5 inhibitors

Mirati Therapeutics, Inc.

12/30/22

2D 3D TSV

70

Macrocyclic chlorine substituted indole derivatives

Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.

12/30/22

2D 3D TSV

6

Method for treating inflammation

KING FAISAL UNIVERSITY

12/30/22

2D 3D TSV

225

OX2R compounds

TBA

12/30/22

2D 3D TSV

14

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

The Johns Hopkins University

12/30/22

2D 3D TSV

154

Small molecule modulators of the BTB domain of Keap1

MedImmune Limited

12/30/22

2D 3D TSV

4

Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase

Newave Pharmaceutical Inc.

12/30/22

2D 3D TSV

4

HGNC:4849 4848

Substituted piperidine compounds and their use

Eisai R&D Management Co., Ltd.

12/30/22

2D 3D TSV

5

Targeted drug rescue with novel compositions, combinations, and methods thereof

TBA

12/30/22

2D 3D TSV

24

Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors

Bristol-Myers Squibb Company

12/30/22

2D 3D TSV

94

HGNC:6307 9967

Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof

BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED

12/30/22

2D 3D TSV

35

1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives and preparation method therefor and use thereof

SOUTHERN MEDICAL UNIVERSITY

12/24/22

2D 3D TSV

27

HGNC:6251 4617

1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A.

12/24/22

2D 3D TSV

52

Acyclic antivirals

JANSSEN PHARMACEUTICA NV

12/24/22

2D 3D TSV

14

Cyclic dinucleotides as sting agonists

Janssen Biotech, Inc.

12/24/22

2D 3D TSV

111

HGNC:8775 8774 8776

Imidazopyrazinones as PDE1 inhibitors

H. Lundbeck A/S

12/24/22

2D 3D TSV

67

HGNC:11778 3531 11779 11777 16255

Inhibitors of blood coagulation factor XIII

Zedira GmbH

12/24/22

2D 3D TSV

172

Inhibitors of cysteine proteases and methods of use thereof

Pardes Biosciences, Inc.

12/24/22

2D 3D TSV

1

Mcl-1 inhibitors and methods of use thereof

AstraZeneca AB

12/24/22

2D 3D TSV

37

HGNC:6190 6192 6193 12440

Pyrazolo[1,5-a]pyrazin-4-yl derivatives

Pfizer Inc.

12/24/22

2D 3D TSV

186

HGNC:262 263 186

Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist

BEIGENE, LTD.

12/24/22

2D 3D TSV

79

Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors

Array BioPharma Inc.

12/24/22

2D 3D TSV

95

Tricyclic compounds and their use as phosphodiesterase inhibitors

PFIZER, INC.

12/24/22

2D 3D TSV

35

Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases

BEIGENE, LTD.

12/23/22

2D 3D TSV

11

Compounds for treatment of hypoproliferative disorders

LU LICENSE AB

12/23/22

2D 3D TSV

27

Diacylglycerol acyl transferase 2 inhibitor

Pfizer Inc.

12/23/22

2D 3D TSV

5

HGNC:2160 2159

Docosahexaenoic acid endocannabinoid epoxide derivative compositions

The Board of Trustees of the University of Illinois

12/23/22

2D 3D TSV

279

Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors

Incyte Corporation

12/23/22

2D 3D TSV

18

Quinazolinones that inhibit the formation of tau oligomers and their method of use

Oligomerix, Inc.

12/23/22

2D 3D TSV

93

RIP1 inhibitory compounds and methods for making and using the same

Rigel Pharmaceuticals, Inc.

12/23/22

2D 3D TSV

146

HGNC:6833 549 6834

SSAO inhibitors and use thereof

Eccogene (Shanghai) Co., Ltd.

12/23/22

2D 3D TSV

19

Sphingosine analogs and use thereof against bacterial lung infections

Yeda Research and Development Co. Ltd.; University of Duisburg-Essen

12/23/22

2D 3D TSV

51

3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

Nurix Therapeutics, Inc.

12/11/22

2D 3D TSV

69

Compound functioning as bromodomain protein inhibitor, and composition

Betta Pharmaceuticals Co., Ltd.

12/11/22

2D 3D TSV

48

Compound having ERK kinase inhibitory activity and use thereof

SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

12/11/22

2D 3D TSV

10

Cyclic di-nucleotide compounds as sting agonists

Merck Sharp & Dohme LLC

12/11/22

2D 3D TSV

13

Heterocyclic compounds as immunomodulators

Incyte Corporation

12/11/22

2D 3D TSV

94

Heterocyclic inhibitors of PTPN11

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

12/11/22

2D 3D TSV

16

Modulators of the NMDA receptor

H. Lundbeck A/S

12/11/22

2D 3D TSV

60

Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof

SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

12/11/22

2D 3D TSV

142

Pharmaceutical compounds

OTSUKA PHARMACEUTICAL CO., LTD.; TAIHO PHARMACEUTICAL CO., LTD.

12/11/22

2D 3D TSV

31

Pyridazines

Boehringer Ingelheim International GmbH

12/11/22

2D 3D TSV

187

HGNC:3023 5286

Substituted lactams showing serotonin 5-HT receptor activity

SUMITOMO PHARMA CO., LTD.

12/11/22

2D 3D TSV

21

Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors

Enanta Pharmaceuticals, Inc.

12/11/22

2D 3D TSV

27

Tricyclic compounds

JACOBIO PHARMACEUTICALS CO., LTD.

12/11/22

2D 3D TSV

15

HGNC:9605 385 9604 386

2-beta-naphthyl-acetic acid analogs as AKR1C3 inhibitors and methods of using same

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; VANDERBILT UNIVERSITY

12/07/22

2D 3D TSV

286

HGNC:6514 6515

6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors

Novartis AG

12/07/22

2D 3D TSV

20

Annulated glycosidase inhibitors

Asceneuron SA

12/07/22

2D 3D TSV

30

Antibacterial compounds

INFEX Therapeutics Limited

12/07/22

2D 3D TSV

140

Biaryl derivative, preparation method thereof and pharmaceutical application thereof

ABBISKO THERAPEUTICS CO., LTD.

12/07/22

2D 3D TSV

72

Broad spectrum antiviral compositions and methods

Evrys Bio, LLC

12/07/22

2D 3D TSV

74

Broad spectrum inhibitors of filoviruses

Microbiotix, Inc.; Albert Einstein College of Medicine; The Government of the United States as Represented by the Secretary of the Army

12/07/22

2D 3D TSV

3

Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors

Suven Life Sciences Limited

12/07/22

2D 3D TSV

3

Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making

PHARMAKEA, INC.

12/07/22

2D 3D TSV

108

Heterocyclic compounds for the inhibition of PASK

BioEnergenix LLC

12/07/22

2D 3D TSV

71

Imidazopyridazine and imidazopyridine compounds and uses thereof

Incyte Corporation

12/07/22

2D 3D TSV

48

Isothiazolo[5,4-D]pyrimidine compound as IRAK4 inhibitor

Chia Tai Tianqing Pharmaceutical Group Co., Inc.

12/07/22

2D 3D TSV

227

Modulators of methyl modifying enzymes, compositions and uses thereof

Constellation Pharmaceuticals, Inc.

12/07/22

2D 3D TSV

160

N/O-linked Degrons and Degronimers for protein degradation

C4 Therapeutics, Inc.

12/07/22

2D 3D TSV

67

Pyrazine carbamates and their use as GluN2B receptor modulators

JANSSEN PHARMACEUTICA NV

12/07/22

2D 3D TSV

5

HGNC:6190 6192 6193 12440

Substituted pyrrolo[2,3-d]pyrimidines as JAK inhibitors

VIMALAN BIOSCIENCES, INC.

12/07/22

2D 3D TSV

229

TEAD inhibitors and uses thereof

IKENA ONCOLOGY, INC.

12/07/22

2D 3D TSV

36

Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors

NIKANG THERAPEUTICS, INC.

12/07/22

2D 3D TSV

15

3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders

MINDSET PHARMA INC.

12/04/22

2D 3D TSV

215

Cyclic di-nucleotide compounds as sting agonists

Merck Sharp & Dohme LLC

12/04/22

2D 3D TSV

25

HGNC:6190 6192 6193 12440

JAK inhibitors containing a 4-membered heterocyclic amide

THERAVANCE BIOPHARMA R&D IP, LLC

12/04/22

2D 3D TSV

452

KRas G12D inhibitors

MIRATI THERAPEUTICS, INC.; ARRAY BIOPHARMA INC.

12/04/22

2D 3D TSV

143

HGNC:336 338

Receptor inhibitor, pharmaceutical composition comprising same, and use thereof

BEIJING TIDE PHARMACEUTICAL CO., LTD.

12/04/22

2D 3D TSV

576

Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

12/04/22

2D 3D TSV

16

HGNC:8783 8775 8774 8776 8778

Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors

ELI LILLY AND COMPANY

12/04/22

2D 3D TSV

72

Substituted eneoxindoles and uses thereof

Gilead Sciences, Inc.

12/04/22

2D 3D TSV

44

Substituted propanamides as inhibitors of nucleases

MASARYKOVA UNIVERZITA

12/04/22

2D 3D TSV

1

HGNC:8031 8032 8033

Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitors

SHENZHEN TARGETRX, INC.

12/04/22

2D 3D TSV

29

Tricyclic compounds useful to treat orthomyxovirus infections

Novartis AG

12/04/22

2D 3D TSV

4

HGNC:1509 1504 1499 1511

(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases

Histogen, Inc.

11/20/22

2D 3D TSV

66

Galactoside inhibitor of galectins

GALECTO BIOTECH AB

11/20/22

2D 3D TSV

49

Macrocyclic chlorine substituted indole derivatives

Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.

11/20/22

2D 3D TSV

225

HGNC:1738 1737 10251 10252

Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer

Cancer Research Technology Limited

11/20/22

2D 3D TSV

12

Tricyclic amine compounds as CDK2 inhibitors

Incyte Corporation

11/20/22

2D 3D TSV

360

Aminoimidazopyridazines as kinase inhibitors

Bristol-Myers Squibb Company

11/19/22

2D 3D TSV

116

Anti-inflammatory compound, and preparation and use thereof

E-Nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

11/19/22

2D 3D TSV

25

Aromatic heterocyclic substituted olefin compound, preparation method for same, pharmaceutical composition of same, and applications thereof

SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

11/19/22

2D 3D TSV

83

Compound exhibiting enteropeptidase inhibitory activity

LG CHEM, LTD.

11/19/22

2D 3D TSV

90

Compounds, salts thereof and methods for treatment of diseases

ACADIA PHARMACEUTICALS INC.

11/19/22

2D 3D TSV

64

Cyclic compound having dopamine D3 receptor antagonistic effect

SHIONOGI & CO., LTD.

11/19/22

2D 3D TSV

10

Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof

Korea Research Institute of Chemical Technology; Industry-Academic Cooperation Foundation, Yonsei University

11/19/22

2D 3D TSV

32

Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors

Recordati Industria Chimica e Farmacentica S.p.A.

11/19/22

2D 3D TSV

33

Indoleamine-2,3-dioxygenase inhibitor, the preparative method and the use thereof

HINOVA PHARMACEUTICALS INC.

11/19/22

2D 3D TSV

95

Inhibitors of cyclin-dependent kinases

TBA

11/19/22

2D 3D TSV

118

Pharmaceutical compounds for treatment of medical disorders

Achillion Pharmaceuticals, Inc.

11/19/22

2D 3D TSV

46

HGNC:6190 6192 6193 12440

Pyrimidine JAK inhibitors for the treatment of skin diseases

THERAVANCE BIOPHARMA R&D IP, LLC

11/19/22

2D 3D TSV

98

HGNC:11584 14552

Pyrimidine TBK/IKKe inhibitor compounds and uses thereof

Merck Patent GmbH

11/19/22

2D 3D TSV

7

Quinoline analogs as phosphatidylinositol 3-kinase inhibitors

NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD.

11/19/22

2D 3D TSV

5

Selective A2A receptor antagonist

INXMED (NANJING) CO., LTD.

11/19/22

2D 3D TSV

94

Spiroheptanyl hydantoins as rock inhibitors

Bristol-Myers Squibb Company

11/19/22

2D 3D TSV

6

Substituted 1,2,3,4-tetrahydroquinolines as inhibitors of repair enzyme 8-oxoguanine deoxyribonucleic acid glycosylase activity

The Board of Trustees of the Leland Stanford Junior University

11/19/22

2D 3D TSV

79

Substituted macrocyclic indole derivatives

TBA

11/19/22

2D 3D TSV

30

HGNC:6877 1079 1133 6171 9611 3236

Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof

TBA

11/19/22

2D 3D TSV

353

Tetrahydroquinoline derivatives as P2X7 receptor antagonists

RaQualia Pharma Inc.; Asahi Kasei Pharma Corporation

11/19/22

2D 3D TSV

22

Triazolo-azepine derivatives

Hoffmann-La Roche Inc.

11/19/22

2D 3D TSV

32

Tricyclic amine compounds as CDK2 inhibitors

Incyte Corporation

11/19/22

2D 3D TSV

10

p38α mitogen-activated protein kinase inhibitors

GEN1E LIFESCIENCES INC.

11/19/22

2D 3D TSV

12

ASK1 inhibitor compounds and uses thereof

SEAL ROCK THERAPEUTICS, INC.

11/13/22

2D 3D TSV

56

ATR inhibitor and application thereof

Wuxi Biocity Biopharmaceutics Co., Ltd.

11/13/22

2D 3D TSV

129

Heterocyclic inhibitors of ATR kinase

Board of Regents, The University of Texas System; ChemPartner Corporation

11/13/22

2D 3D TSV

359

Heterocyclylamines as PI3K inhibitors

Incyte Corporation; Incyte Holdings Corporation

11/13/22

2D 3D TSV